Valuation $2.36 as of 27 Apr 2024Morningstar affirms a 3-star quantitative rating forMesoblast. We calculate this outcome using thecompany's underlying model-driven valuation anduncertainty scores.The stock's last closing price was 0.93, a discountof 60.56% to its Quantitative Fair Value estimate of2.36. This discount has ranged between 66.49%and 20.07% over the past year. The stock's price tofair value ratio is at the 6th percentile in our globalequity coverage universe for this methodology andat the 14th percentile relative to its peers in thehealthcare sector.Mesoblast furthermore
banter and General Discussion, page-9542
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.010(0.92%) |
Mkt cap ! $1.233B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.11 | $1.05 | $5.002M | 4.632M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5697 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
-0.010 ( 0.10 %) |
||||
| Open | High | Low | Volume | ||
| $1.09 | $1.11 | $1.06 | 1181223 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| MSB (ASX) Chart |